Bonus BioGroup Ltd. (TLV:BONS)

Market Cap	199.75M -27.2%
Revenue (ttm)	n/a
Net Income	-23.87M
EPS	n/a
Shares Out	1.17B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,402
Open	17.10
Previous Close	17.10
Day's Range	17.00 - 17.30
52-Week Range	17.00 - 60.90
Beta	0.84
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Bonus BioGroup

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company’s products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1981
• Employees: 42
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: BONS

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error